Calliditas Therapeutics' 2020 Annual Report Published

Rhea-AI Summary

Calliditas Therapeutics AB (Nasdaq: CALT) announces the availability of its 2020 Annual Report on its website. This report provides insights into the company's financial performance and strategic direction, particularly focusing on its lead product, Nefecon, aimed at treating IgA nephropathy. Calliditas is conducting a global Phase 3 study for Nefecon with the intent to commercialize it in the U.S. The announcement complies with the Securities Markets Act, highlighting the company's commitment to transparency.

Positive

• Nefecon is a novel oral formulation targeting IgA nephropathy, addressing a significant unmet medical need.
• Active global Phase 3 study indicates progression towards potential commercialization.

Negative

• No specific financial metrics or results disclosed in the report may lead to uncertainty among investors.

STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: www.calliditas.com.

This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14:30 CET on April 27, 2021.

For further information, please contact:

Marie Galay, IR Manager, Calliditas

Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com

About Calliditas

Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics--2020-annual-report-published,c3334502

The following files are available for download:

https://mb.cision.com/Main/16574/3334502/1408150.pdf	Calliditas AR 2020_EN_
https://mb.cision.com/Public/16574/3334502/83e78aaa2310d2ec.pdf	Annual report 2020 published EN

 

 

 

View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-2020-annual-report-published-301277937.html

SOURCE Calliditas Therapeutics

FAQ

What is included in Calliditas Therapeutics' 2020 Annual Report?

The report includes financial performance insights and details on the company's lead product candidate, Nefecon.

When was the Calliditas Therapeutics 2020 Annual Report published?

The report was published on April 27, 2021.

What is the focus of Calliditas Therapeutics as highlighted in the 2020 Annual Report?

The company focuses on developing treatments for orphan indications, with a primary emphasis on renal diseases.

Where can I access the Calliditas Therapeutics 2020 Annual Report?

The report is available on Calliditas Therapeutics' official website.

What is the significance of Nefecon for Calliditas Therapeutics?

Nefecon is targeting IgA nephropathy, a condition with no approved treatments, representing a key opportunity for the company.